HomeCYBN • NYSEAMERICAN
add
Cybin Inc
$7.70
After Hours:(0.26%)+0.020
$7.72
Closed: Apr 14, 6:52:08 PM GMT-4 · USD · NYSEAMERICAN · Disclaimer
Previous close
$6.80
Day range
$7.12 - $7.96
Year range
$4.81 - $14.44
Avg Volume
222.86K
P/E ratio
-
Dividend yield
-
Market news
MarketWatch
15 hours ago
S&P 500 tallies its first ‘death cross’ in 3 years. Here’s what happens next.
0.79%
Financials
Income Statement
Revenue
Net income
| (CAD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 31.33M | 15.94% |
Net income | -10.54M | 65.24% |
Net profit margin | — | — |
Earnings per share | -0.53 | 84.50% |
EBITDA | -31.28M | -16.41% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (CAD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 136.29M | 249.47% |
Total assets | 253.55M | 95.45% |
Total liabilities | 13.31M | 56.49% |
Total equity | 240.24M | — |
Shares outstanding | 21.04M | — |
Price to book | 0.57 | — |
Return on assets | -30.36% | — |
Return on capital | -31.62% | — |
Cash Flow
Net change in cash
| (CAD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -10.54M | 65.24% |
Cash from operations | -27.12M | -4.15% |
Cash from investing | -303.00K | -104.06% |
Cash from financing | -179.00K | -100.45% |
Net change in cash | -18.03M | -186.34% |
Free cash flow | -17.34M | -88.49% |
About
Cybin IRL is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, CYB002, CYB003, CYB004, CYB005, and CYB006. Another drug that the company has developed is CYB210010.
As of January 2025, CYB003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Cybin acquired psychedelic pharmaceutical company Adelia Therapeutics. Wikipedia
Founded
2019
Headquarters
Website
Employees
50
